众生药业：昂拉地韦片获批上市

Core Viewpoint - The approval of ZHONGSHENG Pharmaceutical's Angladiwe Tablets by the National Medical Products Administration marks a significant advancement in the treatment of influenza, being the first RNA polymerase PB2 protein inhibitor globally [1] Company Summary - ZHONGSHENG Pharmaceutical (002317) announced the approval of Angladiwe Tablets on May 22, 2025, for the treatment of adult uncomplicated influenza A patients [1] - Angladiwe Tablets are the only antiviral drug in China that has undergone head-to-head Phase III clinical trials against Oseltamivir and received market approval [1] Clinical Trial Results - Phase III clinical trial results indicated that Angladiwe Tablets significantly outperformed the placebo group in seven primary endpoints related to the relief of influenza symptoms, achieving statistical significance [1] - The Angladiwe group demonstrated a nearly 10% reduction in median time to alleviation of total symptoms (TTAS) and fever relief compared to the Oseltamivir group [1]